Recent Updates
Recently added Catalysts

G-CSF

Phase 1

Phase I | Small molecule | Oncology |Ascentage Pharma Group International - American Depository Shares|Last Updated: Feb 23, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment24
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07428486A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic LeukemiaPHASE1 NOT YET_RECRUITING 24 — — Aug 17, 2026Jun 12, 2032Feb 23, 20261 United States
Unlock Drug Trial Details
Study Design & Arms
AllocationNA
MaskingNONE
PurposeTREATMENT
Interventions
NameTypeDescription
FludarabineDRUGGiven by IV
CytarabineDRUGGiven by IV
G-CSFDRUGGiven by Injection
LisaftoclaxDRUGGiven by Po
PelcitoclaxDRUGGiven by Iv
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT07428486studyFirstPostDate: changed